Returns At MicroPort NeuroScientific (HKG:2172) Are On The Way Up
Returns At MicroPort NeuroScientific (HKG:2172) Are On The Way Up
0.17 = CN¥299m ÷ (CN¥2.1b - CN¥287m) If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Speaking of which, we noticed some great changes in MicroPort NeuroScientific's (HKG:2172) returns on capital, so let's have a look.
如果你在寻找一只多倍股，有几个要注意的事情。一个常见的方法是找到一个ROCE（资本利用率回报率）在不断增长并且资本利用率不断增加的公司。基本上，这意味着公司拥有有利可图的举措，可以继续投资，这是复利机器的特点。说到这一点，我们注意到微创医疗的资本回报率有一些很好的变化，所以让我们来看一下。
Return On Capital Employed (ROCE): What Is It?
资本雇用回报率（ROCE）是什么？
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on MicroPort NeuroScientific is:
只是为了澄清，如果你不确定，ROCE是评估公司在其业务中投资的资本上赚取多少税前收入（以百分比形式）的指标。这种计算在微创医疗上的公式是：
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
资产雇用回报率（ROCE）是指企业利润，即企业税前利润除以企业投入的总资本（负债加股权）。如果ROCE高于企业财务成本的承受能力，那么企业就会创造出更多的价值。
0.17 = CN¥299m ÷ (CN¥2.1b - CN¥287m) (Based on the trailing twelve months to June 2024).
0.17 = 2,9900万元 ÷ (21亿 - 2,8700万元) （截至2024年6月的过去十二个月）。
Therefore, MicroPort NeuroScientific has an ROCE of 17%. In absolute terms, that's a satisfactory return, but compared to the Medical Equipment industry average of 8.4% it's much better.
因此，微创医疗的ROCE为17%。绝对来说，这是一个满意的回报，但与医疗设备行业的平均8.4%相比，要好得多。
Above you can see how the current ROCE for MicroPort NeuroScientific compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for MicroPort NeuroScientific .
以上是MicroPort神经科学当前ROCE与之前资本回报率的比较，但过去的信息只能告诉您有限的内容。如果您感兴趣，您可以查看我们为MicroPort神经科学提供的免费分析师报告中的分析师预测。
What Does the ROCE Trend For MicroPort NeuroScientific Tell Us?
MicroPort神经科学的ROCE趋势告诉我们什么？
Investors would be pleased with what's happening at MicroPort NeuroScientific. The numbers show that in the last four years, the returns generated on capital employed have grown considerably to 17%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 312%. So we're very much inspired by what we're seeing at MicroPort NeuroScientific thanks to its ability to profitably reinvest capital.
投资者会对MicroPort神经科学发生的事情感到满意。数字显示，在过去的四年中，资本使用率的回报显著增长至17%。该公司有效地创造了更多资本使用的资金，值得注意的是资本量也增加了312%。因此，我们非常受到MicroPort神经科学的启发，这要归功于其能够有利可图地重新投资资本。
The Bottom Line
还有一件事需要注意的是，我们已经确定了上海医药的2个警告信号，了解这些信号应该成为你的投资过程的一部分。
All in all, it's terrific to see that MicroPort NeuroScientific is reaping the rewards from prior investments and is growing its capital base. And since the stock has fallen 35% over the last year, there might be an opportunity here. With that in mind, we believe the promising trends warrant this stock for further investigation.
总的来说，很棒看到MicroPort神经科学正在从先前的投资中获得回报并扩大其资本基础。考虑到过去一年股价下跌了35%，这可能是一个机会。考虑到这一点，我们认为有利的趋势值得进一步调查这支股票。
Before jumping to any conclusions though, we need to know what value we're getting for the current share price. That's where you can check out our FREE intrinsic value estimation for 2172 that compares the share price and estimated value.
然而，在得出任何结论之前，我们需要了解当前股价所得到的价值。这就是您可以查看我们为2172提供的免费内在价值估算，从中比较股价和预估价值。
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
如果您想寻找财务状况良好、回报卓越的实力强企业，可以免费查看以下公司列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈？对内容有任何疑虑？请直接与我们联系。或者，发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。